诺和诺德肥胖症药物在哥本哈根试验中不敌礼来药物

路透中文
Feb 23
<a href="https://laohu8.com/S/NVO">诺和诺德</a>肥胖症药物在哥本哈根试验中不敌<a href="https://laohu8.com/S/LLY">礼来</a>药物

路透哥本哈根2月23日 - 诺和诺德>周一称,其试验性肥胖症药物CagriSema没有达到一项试验的主要终点,该试验旨在证明该药物在减轻体重方面不劣于竞争对手礼来公司的Tirzepatide。

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10